In addition, targeting FTO decreased the expression of immune checkpoints, such as PD-L1, PD-L2, and LILRB, to reverse immune evasion of leukemia cells (Su et al., 2020), highlighting the potential of FTO inhibitors for cancer therapy. The gene discussed is FTO; the disease is leukemia.